EyePoint Pharmaceuticals (EYPT) Accumulated Expenses: 2011-2019
Historic Accumulated Expenses for EyePoint Pharmaceuticals (EYPT) over the last 8 years, with Mar 2019 value amounting to $2.9 million.
- EyePoint Pharmaceuticals' Accumulated Expenses fell 9.05% to $2.9 million in Q1 2019 from the same period last year, while for Mar 2019 it was $2.9 million, marking a year-over-year decrease of 9.05%. This contributed to the annual value of $3.7 million for FY2018, which is 11.86% down from last year.
- EyePoint Pharmaceuticals' Accumulated Expenses amounted to $2.9 million in Q1 2019, which was down 22.83% from $3.8 million recorded in Q4 2018.
- In the past 5 years, EyePoint Pharmaceuticals' Accumulated Expenses registered a high of $4.2 million during Q2 2017, and its lowest value of $1.4 million during Q1 2015.
- Over the past 3 years, EyePoint Pharmaceuticals' median Accumulated Expenses value was $3.3 million (recorded in 2018), while the average stood at $3.3 million.
- In the last 5 years, EyePoint Pharmaceuticals' Accumulated Expenses skyrocketed by 146.39% in 2016 and then slumped by 38.55% in 2017.
- Quarterly analysis of 5 years shows EyePoint Pharmaceuticals' Accumulated Expenses stood at $3.6 million in 2015, then climbed by 3.63% to $3.7 million in 2016, then tumbled by 38.55% to $2.3 million in 2017, then skyrocketed by 67.51% to $3.8 million in 2018, then fell by 9.05% to $2.9 million in 2019.
- Its Accumulated Expenses was $2.9 million in Q1 2019, compared to $3.8 million in Q4 2018 and $3.3 million in Q3 2018.